uplizna
horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - imunosupresoare - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.
natalizumab elan pharma
elan pharma international ltd. - natalizumab - crohn boala - imunostimulante, - tratamentul activă moderată până la severă boala crohn pentru reducerea semnelor și a simptomelor, și de inducție și de întreținere a răspuns susținut la tratament și remisie, la pacienții care nu au răspuns, în ciuda unei cure complete și adecvate de terapie cu corticosteroizi și imunosupresoare; sau care nu tolerează sau prezintă contraindicații pentru astfel de terapii.
trogarzo
theratechnologies europe limited - ibalizumab - infecții cu hiv - antivirale pentru uz sistemic - trogarzo, în asociere cu alte antiretrovirale(s), este indicat pentru tratamentul adulților infectați cu tuberculoza multidrog rezistente la infecția cu hiv-1, pentru care este de altfel imposibil de a construi o supresie tratament antiviral.
tyruko
sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresoare - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri
biogen netherlands b.v. - natalizumab - scleroză multiplă - imunosupresoare selective - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 și 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
tysabri 150mg
biogen (denmark) manufacturing aps - danemarca - natalizumabum - sol. inj. in seringa preumpluta - 150mg - imunosupresoare imunosupresoare selective
tysabri 300mg
biogen (denmark) manufacturing aps - danemarca - natalizumabum - conc. pt. sol. perf. - 20mg/ml - imunosupresoare imunosupresoare selective
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - fumarat de dimetil - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
fingolimod zentiva 0,5 mg
zentiva s.a. - romania - fingolimodum - caps. - 0,5mg - imunosupresoare imunosupresoare selective
fingolimod tiefenbacher 0,5 mg
delorbis pharmaceuticals ltd. - cipru - fingolimodum - caps. - 0,5mg - imunosupresoare imunosupresoare selective